Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04393454 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04393454 is a Phase 2 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 6 participants.
The verdict
NCT04393454, a Phase 2 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
To evaluate the efficacy of sirolimus by estimating the overall response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) in patients with metastatic dMMR solid cancer after immunotherapy (either due to disease progression or to inability to tolerate treatment).
Interventions
- DRUG Sirolimus 2mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04393454
The ClinicalTrials.gov registry entry for NCT04393454 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sirolimus 2mg Tablet is the first listed.
NCT04393454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04393454 about?
NCT04393454 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy". To evaluate the efficacy of sirolimus by estimating the overall response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) in patients with metastatic dMMR solid cancer after immunotherapy (either due to disease progression or to inability to tolerate t...
What is the current status of trial NCT04393454?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-11-16. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT04393454?
The interventions under investigation include: Sirolimus 2mg Tablet (DRUG).
Who is sponsoring clinical trial NCT04393454?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.